<h2>最新季度如何重塑 Teleflex 的故事</h2>
<p>Teleflex (TFX) 刚刚发布了一个季度的财报，收入超出分析师预期，管理层指出收购的血管介入业务和血管及外科产品的稳定需求作出了贡献。</p>
<p>这一财报背景，包括关于有利订单时机和一些临时整合相关干扰的评论，提供了关于 Teleflex 的增长努力和收购活动如何影响当前运营表现的最新信息。</p>
<p>请查看我们对 Teleflex 的最新分析。</p>
<p>Teleflex 最近的盈利超出预期，确认了 2026 年的收入指引，并宣布了新的季度股息，同时其股价在 90 天内回报率达 23.19%。然而，五年总股东回报率下降了 66.58%，突显出近期反弹与长期表现疲弱之间的对比。</p>
<p>如果这种复苏与过去的挫折让你考虑多元化，值得通过我们关注医疗科技的 31 家医疗 AI 股票来寻找其他医疗科技公司。</p>
<p>目前 Teleflex 的交易价格为 130.41 美元，约比分析师平均目标价低 10%，与一些内在价值估计之间的差距更大，这一近期反弹是早期入场的机会，还是市场已经在考虑未来增长的预期？</p>
<h2>最受欢迎的叙述：1% 被高估</h2>
<p>Teleflex 最受关注的估值叙述将公允价值定为 129.25 美元，略低于最后收盘价 130.41 美元，这形成了紧密的估值差距。</p>
<blockquote>
<p><em>公司专注于投资组合优化和潜在的业务部门分离或出售（例如，新公司），预计所得款项将用于偿还债务和回报股东，这可能会释放价值并通过更专注、精简的运营模式提高净利润率和每股收益。</em></p>
</blockquote>
<p><em>阅读完整叙述。</em> 阅读完整叙述。</p>
<p>想看看在公允价值的适度溢价下有什么？该叙述在很大程度上依赖于提升的盈利能力、更高的利润率，以及假设 Teleflex 进入更高质量区间的未来估值倍数。</p>
<p><strong>结果：公允价值为 129.25 美元（被高估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，仍然存在压力点，包括 UroLift 的持续疲软和 BIOTRONIK 血管介入交易的整合风险，这可能会挑战更高质量的前景。</p>
<p>了解这一 Teleflex 叙述的关键风险。</p>
<h2>关于 Teleflex 价值的另一种看法</h2>
<p>流行的叙述依赖于盈利和利润假设，但 SWS DCF 模型呈现了不同的观点。根据该模型，Teleflex 在 130.41 美元时约低于估计的未来现金流价值 223.56 美元 42%，这表明市场可能已经在定价实质性的执行风险。你认为哪种解释与数字更为接近？</p>
<p>了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61183de2-c28b-4b5c-b21c-0e343807b52c/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61183de2-c28b-4b5c-b21c-0e343807b52c/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE5"/></p>
<p>截至 2026 年 5 月的 TFX 折现现金流</p>
<h2>下一步</h2>
<p>如果这种机会与担忧的组合感觉微妙平衡，现在是直接审查数据并权衡双方的好时机。首先关注 2 个关键收益和 3 个重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果你在考虑 Teleflex 之后的下一步，扩大视野，查看来自 Simply Wall St 筛选器的几份专注股票想法列表是有意义的。</p>
<ul>
<li>通过扫描结合优质基本面与吸引定价的公司，寻找潜在价值机会，使用 52 家高质量被低估股票。</li>
<li>通过 12 家股息堡垒发现提供更高收益的公司，增强你的收入观察列表。</li>
<li>通过关注 65 家低风险评分的稳健股票，降低意外风险。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，性质一般。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3>估值复杂，但我们在这里简化它。</h3>
<p>通过我们的详细分析，发现 Teleflex 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

泰利福

<p>泰利福 (Teleflex, TFX) 报告的季度收益超出预期，得益于其血管介入收购和稳定的需求。尽管最近股价上涨了 23.19%，但五年总股东回报率下降了 66.58%。分析师认为，TFX 的当前股价 130.41 美元略显高估，公允价值估计为 129.25 美元。然而，DCF 模型显示未来现金流的潜在价值为 223.56 美元，这表明市场定价可能反映了执行风险。投资者被鼓励在分析中考虑机会和风险</p>

<h2>How the latest quarter reshaped the Teleflex story</h2>
<div class="lb-trans"><h2>最新季度如何重塑 Teleflex 的故事</h2>
</div><p>Teleflex (TFX) just delivered a quarter where revenue came in ahead of analyst expectations, with management pointing to contributions from the acquired Vascular Intervention business and steady demand in vascular and surgical products.</p>
<div class="lb-trans"><p>Teleflex (TFX) 刚刚发布了一个季度的财报，收入超出分析师预期，管理层指出收购的血管介入业务和血管及外科产品的稳定需求作出了贡献。</p>
</div><p>This earnings backdrop, including comments about favorable order timing and some temporary integration related disruption, provides updated information on how Teleflex’s growth efforts and acquisition activity are influencing current operating performance.</p>
<div class="lb-trans"><p>这一财报背景，包括关于有利订单时机和一些临时整合相关干扰的评论，提供了关于 Teleflex 的增长努力和收购活动如何影响当前运营表现的最新信息。</p>
</div><p>See our latest analysis for Teleflex.</p>
<div class="lb-trans"><p>请查看我们对 Teleflex 的最新分析。</p>
</div><p>Teleflex’s recent earnings beat, confirmed 2026 revenue guidance and a fresh quarterly dividend have come alongside a 90 day share price return of 23.19%. However, the 5 year total shareholder return is down 66.58%, highlighting a recent rebound set against a much weaker long term record.</p>
<div class="lb-trans"><p>Teleflex 最近的盈利超出预期，确认了 2026 年的收入指引，并宣布了新的季度股息，同时其股价在 90 天内回报率达 23.19%。然而，五年总股东回报率下降了 66.58%，突显出近期反弹与长期表现疲弱之间的对比。</p>
</div><p>If this mix of recovery and past setbacks has you thinking about diversification, it could be worth scanning for other medical technology names through our healthcare focused 31 healthcare AI stocks</p>
<div class="lb-trans"><p>如果这种复苏与过去的挫折让你考虑多元化，值得通过我们关注医疗科技的 31 家医疗 AI 股票来寻找其他医疗科技公司。</p>
</div><p>With Teleflex trading at $130.41, sitting at roughly a 10% discount to the average analyst price target and a much larger gap to some intrinsic value estimates, is the recent rebound an early entry point, or is the market already factoring in expectations for future growth?</p>
<div class="lb-trans"><p>目前 Teleflex 的交易价格为 130.41 美元，约比分析师平均目标价低 10%，与一些内在价值估计之间的差距更大，这一近期反弹是早期入场的机会，还是市场已经在考虑未来增长的预期？</p>
</div><h2>Most Popular Narrative: 1% Overvalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：1% 被高估</h2>
</div><p>Teleflex’s most followed valuation narrative pegs fair value at $129.25, slightly below the last close at $130.41, which sets up a tight valuation gap.</p>
<div class="lb-trans"><p>Teleflex 最受关注的估值叙述将公允价值定为 129.25 美元，略低于最后收盘价 130.41 美元，这形成了紧密的估值差距。</p>
</div><blockquote>
<p><em>The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>公司专注于投资组合优化和潜在的业务部门分离或出售（例如，新公司），预计所得款项将用于偿还债务和回报股东，这可能会释放价值并通过更专注、精简的运营模式提高净利润率和每股收益。</em></p>
</blockquote>
</div><p><em>Read the complete narrative.</em> Read the complete narrative.</p>
<div class="lb-trans"><p><em>阅读完整叙述。</em> 阅读完整叙述。</p>
</div><p>Want to see what sits underneath that modest premium to fair value? The narrative leans heavily on stepped up earnings power, richer margins, and a future valuation multiple that assumes Teleflex earns its way into a higher quality bracket.</p>
<div class="lb-trans"><p>想看看在公允价值的适度溢价下有什么？该叙述在很大程度上依赖于提升的盈利能力、更高的利润率，以及假设 Teleflex 进入更高质量区间的未来估值倍数。</p>
</div><p><strong>Result: Fair Value of $129.25 (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 129.25 美元（被高估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, there are still pressure points, including ongoing weakness in UroLift and integration risk around the BIOTRONIK Vascular Interventions deal, which could challenge that higher quality outlook.</p>
<div class="lb-trans"><p>然而，仍然存在压力点，包括 UroLift 的持续疲软和 BIOTRONIK 血管介入交易的整合风险，这可能会挑战更高质量的前景。</p>
</div><p>Find out about the key risks to this Teleflex narrative.</p>
<div class="lb-trans"><p>了解这一 Teleflex 叙述的关键风险。</p>
</div><h2>Another Take On Teleflex’s Value</h2>
<div class="lb-trans"><h2>关于 Teleflex 价值的另一种看法</h2>
</div><p>The popular narrative leans on earnings and margin assumptions, but the SWS DCF model presents a different view. According to that model, Teleflex at $130.41 is about 42% below an estimated future cash flow value of $223.56, which suggests the market could be pricing in substantial execution risk already. Which interpretation do you think aligns more closely with the numbers?</p>
<div class="lb-trans"><p>流行的叙述依赖于盈利和利润假设，但 SWS DCF 模型呈现了不同的观点。根据该模型，Teleflex 在 130.41 美元时约低于估计的未来现金流价值 223.56 美元 42%，这表明市场可能已经在定价实质性的执行风险。你认为哪种解释与数字更为接近？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61183de2-c28b-4b5c-b21c-0e343807b52c/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE5" alt="" original-src="https://images.simplywall.st/company/61183de2-c28b-4b5c-b21c-0e343807b52c/chart/dcf?date=2026-05-19"/></p>
<p>TFX Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TFX 折现现金流</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>If this mix of opportunity and concern feels finely balanced, now is a good time to review the data directly and weigh both sides for yourself. Start with the 2 key rewards and 3 important warning signs.</p>
<div class="lb-trans"><p>如果这种机会与担忧的组合感觉微妙平衡，现在是直接审查数据并权衡双方的好时机。首先关注 2 个关键收益和 3 个重要警示信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If you are weighing what comes next after Teleflex, it makes sense to widen the lens with a few focused stock idea lists from the Simply Wall St screener.</p>
<div class="lb-trans"><p>如果你在考虑 Teleflex 之后的下一步，扩大视野，查看来自 Simply Wall St 筛选器的几份专注股票想法列表是有意义的。</p>
</div><ul>
<li>Target potential value opportunities by scanning companies that combine quality fundamentals with attractive pricing using the 52 high quality undervalued stocks.</li>
<li>Strengthen your income watchlist by spotting companies offering higher yields through the 12 dividend fortresses.</li>
<li>Lower the risk of surprises by focusing on companies with steadier profiles using the 65 resilient stocks with low risk scores.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描结合优质基本面与吸引定价的公司，寻找潜在价值机会，使用 52 家高质量被低估股票。</li>
<li>通过 12 家股息堡垒发现提供更高收益的公司，增强你的收入观察列表。</li>
<li>通过关注 65 家低风险评分的稳健股票，降低意外风险。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质一般。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里简化它。</h3>
</div><p>Discover if Teleflex might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Teleflex 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

在季度收益超预期以及血管介入整合取得进展后，审视泰利福 (TFX) 的估值